Login to Your Account



Clinic Roundup


Wednesday, March 30, 2011
Onyx Pharmaceuticals Inc., of Emeryville, Calif., is expanding its Phase III European FOCUS trial, which is evaluating the efficacy and tolerability of carfilzomib, a next-generation proteasome inhibitor, in patients with relapsed and refractory myeloma. Based on overall survival data from the Phase IIb 003-A1 study, the company is changing the primary endpoint of the FOCUS trial from progression-free survival to overall survival.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription